---
title: "Maharashtra FDA Revokes License of Pune Pharma Firm Following Dangerous Contamination"
url: https://projectchintan.com/article/maharashtra-fda-cancels-inducare-pharma-license-contamination-10pms
publisher: Project Chintan
author: Project Chintan Newsroom
section: India
published: 2026-08-08T05:39:38.000Z
modified: 2026-08-08T09:03:41.841Z
language: en-IN
---

# Maharashtra FDA Revokes License of Pune Pharma Firm Following Dangerous Contamination

State regulators permanently shuttered InduCare Pharma Pvt. Ltd. after discovering insects, larvae, and fungal growth in Ayurvedic treatments. The crackdown follows multiple inspections that exposed systemic failures in hygiene and manufacturing protocols.

## Key takeaways

- Maharashtra FDA permanently revoked InduCare Pharma's license on August 6, 2026, due to severe quality failures.
- Laboratory tests confirmed fungal growth, insects, and larvae in six different Ayurvedic medicine formulations.
- The facility lacked essential manufacturing records, pest control, and proper sanitation standards required by law.
- FDA Commissioner Tukaram Mundhe warned of zero tolerance for manufacturers who neglect safety and quality standards.

## Regulatory Shutdown in Pune

The Maharashtra Food and Drug Administration (FDA) has permanently rescinded the manufacturing license of Pune-based InduCare Pharma Pvt. Ltd. as of August 6, 2026. This decisive enforcement follows the discovery of severe contamination in six specific Ayurvedic products and widespread disregard for Good Manufacturing Practice (GMP) standards. Officials moved to shut down operations after two separate inspections of the facility confirmed that the company was producing substandard medicine.

## Contamination and Missing Ingredients

Laboratory analysis of seized samples revealed alarming physical and microbial defects. Specifically, the FDA identified fungal growth in samples of Sinhanad Guggul and Punarnavadi Mandur, both of which failed microbial limit tests. Even more concerning was the discovery of insects, larvae, and various foreign impurities within Hingvastak Churna and Triphala Churna. Additional products, including Triphala Guggul and Kanchanar Guggul, were found to exceed safety limits for microbial activity.

Beyond physical contamination, investigators determined that the firm failed to include essential ingredients mandated by approved Ayurvedic formulations. The FDA noted that the manufacturer exhibited gross negligence by omitting these required components during the production process.

## Systemic Operational Failures

The inspection reports detailed a facility in significant disarray. Regulators documented damaged equipment, poor sanitation, and a total lack of pest-control records. Furthermore, the company failed to maintain adequate laboratory facilities or consistent records for batch manufacturing, testing, and distribution. A critical lack of sales records for products under complaint hindered the agency's ability to trace potentially harmful batches in the market.

FDA Commissioner Tukaram Mundhe stated that providing safe and effective medicine is the administration's primary duty. He emphasized that manufacturers are legally obligated to follow the Drugs and Cosmetics Act, 1940, and that any negligence regarding drug quality will meet strict regulatory consequences. The company failed to justify these lapses during a show-cause hearing and subsequent joint inspections.

## Key Facts

- The permanent license cancellation occurred on August 6, 2026, following a two-month enforcement campaign.
- Six specific Ayurvedic medicines were classified as 'Not of Standard Quality' due to biological contaminants.
- Violations included the presence of insects, larvae, and fungi in products intended for human consumption.
- The firm violated the Drugs and Cosmetics Act, 1940, and associated 1945 Rules by failing to maintain distribution and batch records.

Source: The Hindu — National

---
Canonical: https://projectchintan.com/article/maharashtra-fda-cancels-inducare-pharma-license-contamination-10pms
Reported from: The Hindu — National